Cargando…

Trials in rare diseases: the need to think differently

Detalles Bibliográficos
Autores principales:	Billingham, Lucinda, Malottki, Kinga, Pritchard, Mark, Steven, Neil
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Invited Speaker Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3287679/ http://dx.doi.org/10.1186/1745-6215-12-S1-A107

Ejemplares similares

Insights from monkey malaria that can change thinking about human infections
por: Cox-Singh, Janet
Publicado: (2010)

Reviewing the evidence supporting predictive biomarkers in European medicines agency indications and contraindications using visual plots
por: Malottki, Kinga, et al.
Publicado: (2015)

Myths, need, contribution to the diagnosis
por: Bozzao, Alessandro
Publicado: (2015)

The rare biosphere: sorting out fact from fiction
por: Sogin, Mitchell L, et al.
Publicado: (2010)

Do we need to demonstrate Amyloid in tissue?
por: Magy, Laurent
Publicado: (2015)

Deciphering the genetic basis of common diseases by integrated functional annotation of common and rare variants
por: Harismendy, Olivier, et al.
Publicado: (2010)

PReS13-SPK-1576: Unmeet needs in JIA treatment
por: Ruperto, N
Publicado: (2013)

Do we need to demonstrate amyloid in tissue for hereditary ATTR amyloidosis ?
por: Westermark, Per
Publicado: (2015)

Using economic modelling to contribute to the prioritisation and design and clinical trials: ready for prime time
por: Sculpher, Mark
Publicado: (2011)

Biotech Eucalyptus can sustainably address society’s need for wood: the example of freeze tolerant Eucalyptus in the southeastern U.S
por: Hinchee, Maud, et al.
Publicado: (2011)

Stratified medicine in practice: review of predictive biomarkers in European Medicines Agency (EMA) indications
por: Malottki, Kinga, et al.
Publicado: (2011)

Analysis of 2,440 human exomes highlights the evolution and functional impact of rare coding variation
por: Akey, Joshua
Publicado: (2011)

Equivalence and non inferiority trials
por: D’Agostino, Ralph B
Publicado: (2011)

EDI200 therapeutic trial
por: Huttner, Kenneth
Publicado: (2012)

The madness of HIV prevention trials
por: McCormack, S
Publicado: (2015)

Discussion session: biomarker trials
Publicado: (2015)

Investigator led trials: challenges and opportunities
por: Sandercock, Peter
Publicado: (2011)

Seven myths of randomisation in clinical trials
por: Senn, Stephen
Publicado: (2011)

Randomised controlled trials of complex interventions
por: Norrie, John
Publicado: (2011)

Removing unnecessary obstacles to randomised trials
por: Collins, Rory
Publicado: (2013)

Peach allergy: different clinical profiles across Europe
por: Fernandez-Rivas, Montserrat
Publicado: (2011)

Disability and quality of life in patients with different forms of migraine
por: D'Amico, Domenico, et al.
Publicado: (2015)

Strategies for handling missing data in randomised trials
por: White, Ian R
Publicado: (2011)

Identifying appropriate phase II trial designs
por: Brown, Sarah R
Publicado: (2011)

Using biomarkers prospectively in adaptive clinical trials
por: Berry, Donald A
Publicado: (2011)

Comparative analysis of the vaginal microbiome in health and disease
por: White, Bryan A, et al.
Publicado: (2011)

Science in a crisis: conducting clinical trials in an emergency
por: Horby, P
Publicado: (2015)

Survival analysis: coping with non proportional hazards in randomized trials
por: Royston, Patrick, et al.
Publicado: (2011)

The UK Medical Research Council and clinical trials, 1934-1960
por: Chalmers, Iain
Publicado: (2013)

Science, society and biosafety of a field trial with transgenic biofuel poplars
por: Van Acker, Rebecca, et al.
Publicado: (2011)

Recruitment to trials - why is it hard and how might we make it less so?
por: Treweek, Shaun
Publicado: (2011)

When to decide to enroll a TTR-FAP patient in a Clinical Trial?
por: Buades, Juan
Publicado: (2015)

INSP-04. Confirmatory adaptive designs for survival trials with several time-to-event endpoints
por: Schmidt, Rene
Publicado: (2022)

Streamlining regulation of clinical trials – update on the Academy of Medical Sciences review and government’s response
por: Ford, Gary A
Publicado: (2011)

Statistical issues in the analysis of non-pharmacological therapy trials with clustering by care-provider or therapy group
por: Roberts, Chris
Publicado: (2011)

Ceoliac disease
por: Troncone, Riccardo
Publicado: (2011)

Missing heritability and missing Fst of candidate genes: why does gene variation differ from trait variation in trees?
por: Kremer, Antoine
Publicado: (2011)

Bioinformatic analysis of allergens
por: Gendel, Steven
Publicado: (2011)

Cardiovascular disease and HIV
por: Martínez, Esteban
Publicado: (2010)

Epigenetics in rheumatic diseases
por: Gay, Steffen
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_4mjhpkejffb4gjpjf8ea1jdmrg